The effects of the combination of sodium ferulate and oxymatrine on lipopolysaccharide-induced acute lung injury in mice.
In our previous study, the remarkable analgesic and anti-inflammatory effects of the combination of sodium ferulate (SF) and oxymatrine (OMT) had been found. In this study, we investigated the effect of the combination of SF and OMT on acute lung injury using lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model. The cell counting and the protein concentration in the bronchoalveolar lavage fluid (BALF) were measured. The animal lung edema degree was evaluated by wet/dry weight (W/D) ratio. The superoxidase dismutase (SOD) activity and myeloperoxidase (MPO) activity was assayed by SOD and MPO kits, respectively. The levels of inflammatory mediators including C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were assayed by enzyme-linked immunosorbent assay method. The data showed that treatment with the combination of SF and OMT markedly attenuated inflammatory cell numbers and protein concentration in the BALF and improved SOD activity and inhibited MPO activity compared to LPS group. Moreover, the combination significantly inhibited the production of CRP and TNF-α in lung homogenate. The histological changes of the lungs were also more significantly improved by the combination. At the same dose, the obvious protective effect was not found in SF or OMT-treated alone group except that the protein concentration slightly decreased in SF group. The results indicated that the combination SF and OMT had a protective effect on LPS-induced ALI in mice, and the effect was much better than that of SF or OMT used alone.
School of Pharmacy, Yantai University, No. 30, Qingquan Road, Laishan District, Yantai, Shandong 264005, People's Republic of China.
Xiaopei
X
Yuan
Yuyun
Y
Wang
Dunren
D
Du
Zhao
Z
Hu
Mengxin
M
Xu
Mingbo
M
Xu
Zhifeng
Z
Liu
D055371:Acute Lung Injury / Q000188:drug therapy*; D000470:Alkaloids / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002097:C-Reactive Protein / Q000032:analysis; D003373:Coumaric Acids / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004338:Drug Combinations; D004487:Edema / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008070:Lipopolysaccharides; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D051379:Mice; D009195:Peroxidase / Q000378:metabolism; D011807:Quinolizines / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D013482:Superoxide Dismutase / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D000093842:Matrines
D000470:Alkaloids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002097:C-Reactive Protein; D003373:Coumaric Acids; D004338:Drug Combinations; D008070:Lipopolysaccharides; D009195:Peroxidase; D011807:Quinolizines; D013482:Superoxide Dismutase; D014409:Tumor Necrosis Factor-alpha; C037573:oxymatrine; D000093842:Matrines; C004999:ferulic acid